



DOCKET NO: C01040.70010.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Heather L. Davis et al.  
Serial No: 09/768,012  
Confirmation No: 9273  
Filed: January 22, 2001  
For: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR  
INDUCING A TH2 IMMUNE RESPONSE  
Examiner: D. Nguyen  
Art Unit: 1632

RECEIVED  
AUG 12 2003  
TECH CENTER 1600/2900

#19

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 5<sup>th</sup> day of August, 2003.

  
Michelle M. Quinn

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART III: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

BEST AVAILABLE COPY



Form 1449/A and B (Modified)

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICATION NO.: 09/768,012

ATTY. DOCKET NO.: C01040.70010.US

FILING DATE: January 22, 2001

CONFIRMATION NO.: 9273

APPLICANT: Heather L. Davis et al.

GROUP ART UNIT: 1632

EXAMINER: D. Nguyen

Sheet 1 of 2

RECEIVED  
AUG 2 2003  
TECH CENTER 1600/2000

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A33	5,268,365		Rudolph et al.	12-07-1993
	A34	5,488,039		Masor et al.	01-30-1996
	A35	5,492,899		Masor et al.	02-20-1996
	A36	5,591,721		Agrawal et al.	01-07-1997
	A37	5,602,109		Masor et al.	02-11-1997
	A38	5,612,060		Alexander	03-18-1997
	A39	5,700,590		Masor et al.	12-23-1997
	A40	5,786,189		Locht et al.	07-28-1998
	A41	6,339,068		Davis et al.	01-15-2002
	A42	6,429,199		Krieg et al.	08-06-2002
	A43	6,406,705		Davis et al.	06-18-2002

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B47	WO	00/03683		Inex Pharmaceuticals Corporation	01-27-2000	
	B48	WO	99/55743		Inex Pharmaceuticals Corporation	11-04-1999	
	B49	WO	98/51278		Inex Pharmaceuticals Corporation	11-19-1998	

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C86	Agrawal, <i>Tibtech</i> , 14:376-387, 1996	
	C87	Bates et al., <i>J. Bio. Chem.</i> , 274(37):26369-26377, 1999	
	C88	Boggs, et al. <i>Antisense Nucleic Acid Drug Dev</i> , 7(5):461-471, 1997	
	C89	Carter et al., <i>Int. J. Immunopharmac.</i> , 13(1):69-76, 1991	
	C90	Chace et al., <i>Clinical Immunology and Immunopathology</i> , 68(3):327-332, 1993	

EXAMINER


DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

BEST AVAILABLE COPY



FORM 1516-1449/A and B (Modified)

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICATION NO.: 09/768,012

ATTY. DOCKET NO.: 01040 20010.US

FILING DATE: January 22, 2001

CONFIRMATION NO.: 9273

APPLICANT: Heather L. Davis et al.

GROUP ART UNIT: 1632

EXAMINER: D. Nguyen

Sheet 2 of 2

C91	Daheshia et al., <i>Vaccine</i> , 16(11/12):1103-1110, 1998	
C92	Diamantstein	
C93	Ewel et al., <i>Cancer Res.</i> , 52(11):3005-3010, 1992	
C94	Fynan et al., <i>Proc Natl Acad Sci USA</i> , 90(24):11478-11482, 1993	
C95	Gao et al., <i>Mol Pharmacol</i> , 41:223-229, 1992	
C96	Hadden et al., <i>JAMA</i> 268(20):2964-2969	
C97	Hartmann, <i>Antisense &amp; Nuc. Acid Drug Dev.</i> , 6:291-299, 1996	
C98	Hatzfeld, <i>J. J Exp Med</i> 174:925-929, 1991	
C99	Hefeneider, <i>Clin. Immunol. and Immunopath.</i> , 63(3):245-251, 1992	
C100	Hughes, <i>Antisense Res. &amp; Dev.</i> , 4:211-215, 1994	
C101	Ishikawa, et al., <i>J. Immunol</i> , 150(9):3713-3727, 1993	
C102	Iverson et al., <i>Antisense Research and Development</i> , 4:43-52, 1994	
C103	Johnson, <i>Immunophar &amp; Infectious Diseases</i> , 291-301, 1987	
C104	Karlin et al., <i>J of Virol</i> , 2889-2897, 1994	
C105	Kataoka, et al., <i>Jpn J. Med Sci. Bio</i> , 43:171-182, 1990	
C106	Kern et al., <i>Antimicrob. Agents &amp; Chemo.</i> , 7(6):721-876(1975)	
C107	Khan, <i>Surgery</i> , 118:531-538, 1995	
C108	Krown, S.I., <i>Semin Oncol.</i> , 13(2):207-217, 1986	
C109	Kuramoto et al., <i>Jpn. J. Cncr Res.</i> , 83:1128-1131, 1992	
C110	Kuramoto et al., <i>Microbiol. Immunol.</i> , 33(11):929-940, 1989	
C111	Kuramoto et al., <i>Int. Immuno-pharmacol.</i> , 14(5):773-782, 1992	
C112	Lacour, et al., <i>J. Biol. Resp. Mod.</i> , 4:538-543, 1985	
C113	Levine et al., <i>Cancer Treat. Rep.</i> , 62(11):1907-1913, 1978	
C114	Levy et al., <i>J. Inf. Disease</i> , 133(Supp):A256-A259, 1976	
C115	Lowell, et al., <i>J. of Infec. Disease</i> , 175:292-301, 1997	
C116	Mashiba, et al., <i>Jpn. J. Med. Sci. Biol.</i> , 41:197-202, 1988	
C117	Michelson et al., <i>Proc. Soc. Exper. Biol. and Med.</i> , 179:180-186, 1985	
C118	Park et al., <i>J. Immunopharm</i> , 17(6):513-515, 1995	
C119	Pisetsky, <i>Antisense Research and Development</i> , 5(3):219-225 (1995)	
C120	Stull et al., <i>Pharmaceutical Res.</i> , 12(4):465-483, 1995	
C121	Threadgill, et al., <i>Vaccine</i> , 16(1):76-82, 1998	
C122	Tursz et al., <i>Immuno. Prosepects of Infectious Diseses</i> , 263-272, 1990	
C123	Uhlmann et al., <i>Chemical Reviews</i> , 90(4):543-584, 1990	
C124	Wiltout, et al., <i>J. Biol. Resp. Mod.</i> , 4(5):512-7, 1985	
C125	Xin, et al., <i>Immunology</i> , 94:438-444, 1998	

EXAMINER

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

BEST AVAILABLE